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Background: The emergence of drug resistance in cancer patients limits the success rate of clinical chemotherapy.
MicroRNAs (miRNAs) may play a role in chemoresistance and may be involved in modulating of some drug
resistance-related pathways in cancer cells. In this study, the involvement of microRNA-148b (miR-148b) and its
roles in the development of chemoresistance in lung cancer are determined.
Methods: This study was performed in two lung cancer cell lines (A549 and SPC-A1). The levels of miR-148b and
DNMT1 mRNA expression were determined by using Quantitative Real-Time PCR. Proteins of DNMTs are represented
by western blot assay. Cell viability was assessed by MTT assay. Cell apoptosis was evaluated using flow cytometry.
Results: The data showed a down-regulated of miR-148b expression and evaluated methyltransferases (DNMTs)
expression in cisplatin-resisted human non-small cell lung cancer (NSCLC) cell line-A549/DDP and SPC-A1/DDP
compared with their parental A549 and SPC-A1 cell line. In transfection experiments, miR-148b mimics reduced
the DNMT1 expression, as well as enhanced the sensitivity of cells to cisplatin and cisplatin-induced apoptosis in
A549/DDP or SPC-A1/DDP cells. While miR-148b inhibitor increased DNMT1 expression, as well as attenuated the
sensitivity of cells to cisplatin in A549 and SPC-A1 cells. miR-148b was showed to exert negative effect on DNMT1
expression by targeting its 3′UTR in A549/DDP and A549 cells. Importantly, silenced DNMT1 increases cisplatin
sensitivity of A549/DDP cells and over-expressed DNMT1 reverses pro-apoptosis effect of miR-148b mimic.
Conclusions: miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNMT1
expression.
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Lung cancer is regarded as the leading cause of cancer
related deaths worldwide [1]. Among this, non-small cell
lung cancer (NSCLC), which distinguished to small-cell
lung cancer (SCLC) from pathological and histological
characteristics, represents approximately 85% [2] and its
five-year survival is only 15% [3]. Chemotherapy is well
known as the main method to treat lung cancer in earlier
stages of treatment, especially as adjuvant chemotherapy* Correspondence: Chengguang_S@163.com
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unless otherwise stated.after surgery. Although advances in cisplatin-based
chemotherapy have resulted in improving the rate of
survival, their therapeutic efficacy was limited for the
development of cisplatin resistance. Therefore, a good
understanding of the molecular mechanisms underlying
cisplatin resistance development is urgently needed.
microRNAs are small non-coding RNA molecules con-
sisting of 20–24 nucleotides and function as the sup-
pressor for gene expression by interacting with the 3′-
untranslated regions (3′UTRs) of target mRNAs at 5–7
nucleotides. These interactions may lead to either ob-
struction of translation or degradation of the targeted
mRNAs [4]. Dysregulation of miRNAs in cells mays is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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apoptosis and metastasis processes that are important in
the development of cancer [5]. Recently, accumulated stud-
ies have shown that miRNAs may play a role in chemore-
sistance of cancer treatment and may be involved in the
modulation of some drug resistance-related pathways in
some cancer cells.
Although few studied focus on the involvement of
microRNA-148b (miR-148b) in drug resistance-related
miRNAs, it has been described to be down-regulated in
several types of cancers including pancreatic cancer [6,7]
colorectal cancer [8], gastric cancer [9], and basal-line
breast cancer [10]. Furthermore, recent report indicates
that miR-148b acts as a tumor suppressor by targeting
specific oncogenes in NSCLC cells [11]. Importantly,
miR-148a, which is together with miR-148b belonging
to miR-148/152 family, plays an important role in improv-
ing response to chemotherapy in sensitive and resistant
cancers. DNA methyltransferases (DNMTs), functioned
as an important regulator for epigenetic processes of
chemotherapy [12], have been proved to be regulated by
miR-148b [7]. Thus, we hypothesized that miR-148b
might be involved in chemotherapy resistance of NSCLC.
In this study, we focused on the effect of altered miR-
148b expression on cisplatin resistance of A549/DDP
and SPC-A1/DPP cells. We also investigated the possible
targets for miR-148b. This study will help to better under-
stand the biological activities of miR-148b in NSCLC
treatment.
Methods
Cells culture and transfection
Human lung adenocarcinoma cell line (A549 and SPC-A1)
and their cisplatin-resistant variant A549/DDP and
SPC-A1/DDP (purchased from the Academy of Military
Medical Science, Beijing, P.R. China.) were cultured in
RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal calf serum (Gibco), penicillin
(100 μg/mL), and streptomycin (100 mg/mL) in a humidi-
fied atmosphere containing 5% CO2 at 37°C. In order to
maintain cisplatin-resistant phenotype, A549/DDP and
SPC-A1/DDP cells were maintained in the medium add-
itionally contained 2 μg/mL cisplatin (DDP).
The cells were seeded in 6-well plates at 1 × 105 cells/
well followed by cultured for 24 hours and then transfected
with 25 nmol of miR-148b mimics and negative control
mimics (NC), miR-148b inhibitors (anti-miR-148b) and
negative control inhibitors (anti-NC) (RIBO Bio, Guangzhou,
P.R. China) using Lipofectamine 2000 (Invitrogen), ac-
cording to the manufacturer’s protocol. The effect of
mimics or antagomirs of miR-148b was examined in
triplicate at 24 h post-transfection. DNMT1 gene was
knocked down using DNMT1 interfering small RNA
(siRNA), which was obtained from Generay (Generay,Shanghai, China) and transfected into the A549/DDP
cells by Lipofectamine 2000.
Quantitative REAL-TIME PCR
Total RNA was extracted from the cells with the Trizol
Reagent (Invitrogen, Carlsbad, CA, USA). Quantitative
Real-Time PCR (Q-RT-PCR) assays was to quantify the
mature miR-148a and DNMT1 mRNA using fluores-
cent nucleic acid dye. Each sample (1 μg) was reverse-
transcribed into cDNA by using the RevertAidTM First
Strand cDNA Synthesis Kit (Fermentas). Real-time PCR
was performed in the Applied Biosystems 7500 Real-time
PCR system using SYBR Premix ExTagTM (Takara) ac-
cording to the manufacturer's protocols. All reactions
were run in triplicate. The threshold cycle (CT) is defined
as the fractional cycle number at which the fluorescence
passes the fixed threshold. The miR-148b expression levels
were normalized to U6 RNA. And the DNMT1 mRNA
was normalized to β-actin mRNA. The relative expression
was calculated using the comparative CT method.
3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium
bromide (MTT) Assay
The cells separately were seeded in 96-well plates at a
density of 4 × 103 cells/well in culture medium. After
their adherence to the culture dish, cells were incubated
with mimic or inhibitor for miR148b for 24 hours. And
then A549/DDP cells were treated with cisplatin at a series
of concentrations (10, 20, 40, 80, 160 and 320 μg/mL),
while A549 cells were treated with cisplatin at 2, 4, 8, 16,
32 and 64 μg/mL. Next, cells were cultured for an add-
itional 48 hours and cell survival was measured by MTT
assay according to the manufacturer’s instructions. The
resulting absorbance at 490 nm was measured on a
spectrophotometer. The concentration at which drug
produced 50% inhibition of growth (IC50) was estimated
by the relative survival curve.
Western blot
The cells were lyzed in RIPA buffer in the presence of
proteinase inhibitor (Sigma-Aldrich, St. Louis, MO, USA).
Equal amounts of protein was separated on 10% sodium
dedecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to PVDF membrane (Millipore
Corp, Billerica, MA, USA). Membranes were blocked
with 10% skimmed milk followed by incubation with the
antibodies (1:500): anti-DNMT1(sc-10222; Santa Cruz,
CA, USA), anti-DNMT3a (sc-20703; Santa Cruz, CA,
USA), anti-DNMT3b ( sc-10236; Santa Cruz, CA, USA)
and anti-β-Actin (#12620; Cell Signaling Technology, MA,
USA). After washed extensively with 0.1% in phosphate-
buffered saline (PBS), the membranes were incubated
with secondary antibodies (anti-rabbit, 1:1000) conjugated
with horseradish peroxidase. The reaction was detected
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Flow cytometry-based apoptosis
The A549/DDP cells were seeded in 96-well plates at a
density of 4 × 103 cells/well in culture medium and trans-
fected. Twenty-four hours later, 10 μg/mL cisplatin was
added to the medium and the cells were incubated for
48 hours. After incubation, the cells were harvested,
stained with 5 μL annexin V-flourescein isothiocyanate
(FITC) and 10 μL propidium iodide (PI) (20 μg/mL). The
mixture was incubated at room temperature in the dark
for 15 minutes and analyzed by fluorescence-activated cell
sorting (FACS).
Bioinformatics analysis of miR-148b target in DNMT1
Based on bioinformatics analysis, we predicted that hsa-
miR-148b can bind with the 3′UTR region of NADM1
by using four common websites (Target Scan: http://
www.targetscan.org/, miRanda: http://www.microrna.org/,Figure 1 Expression of miR-148b and DNMTs in two cell lines of lung canc
and (B) NDMT1, NDMT3a and NDMT3b using western blot assay in A549/DD
as mean ± SD. *P <0.05 compared with A549.Microcosm: http://www.ebi.ac.uk/enright-srv/microcosm/
cgi-bin/targets/v5/genome.pl, and PITA: http://genie.-
weizmann.ac.il/) (Figure 1A).Plasmid construction and Luciferase reporter assays
For DNMT1 3′UTR reporter assay, cells were placed in
24-well plates (1 × 105 cells per well) and then cotrans-
fected with pGL3-DROSHA 3′UTR-T or pGL3-DROSHA
3′UTR-C and pRL-SV40 (50:1). The mimics and inhibi-
tors of hsa-miR-148b and their negative controls (RIBO
Bio, Guangzhou, P.R. China) were cotransfected with the
reporter plasmids at a final concentration of 20 nmol/μl.
48 hours after transfection in A549/DDP and A549 cells,
luciferase activity in lysates was measured with a Dual-
Luciferase Reporter Assay System (Promega, WI, USA)
and normalized against the activity of the pRL-SV40. The
assays were conducted followed by the manufacture’s
suggestions. Independent triplicate experiments were per-
formed for each plasmid construct.er. Cells were lyzed to detect level of (A) miR-148b using Q-RT-PCR
P, SPC-A1/DDP and their respective parental cells. Data were represented
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All experiments were run in triplicate. All statistical analysis
were performed using SPSS 13.0. Data were expressed as
means ± standard deviation (SD). The difference between
the groups was analyzed using Student’s t test when only
two groups were compared or one-way analysis of variance
(ANOVA) when more than two groups were compared.
Values of P < 0.05 indicate statistical significance.Figure 2 miR-148a modified the cisplatin sensitivity of A549/DDP and SPC
by miR-148b mimic or NC for 24 h, the cells were incubated with various d
cells viability was assessed by MTT assay. In A549/DDP cell, IC50miR-148b m
IC50miR-148b mimic is 44.25 μmol/L, IC50NC is 156.32 μmol/L. (B) After A5
the cells were incubated with various doses of cisplatin (2, 4, 8, 16, 32 μmol/L
IC50miR-148b inhibitor is 45.06 μmol/L, IC50NC is 9.21 μmol/L; in SPC-A1 cell,
A549/DDP cells treated by NC or miR-148b mimic for 24 h, and incubated wi
cytometry. Data were represented as mean ± SD. *P <0.05 compared with ceResults
Differential expression of miR-148b and DNMTs in both
A549/DPP and SPC-A1/DPP cells compared with their
parental cell lines
We detected the expression levels of miR-148b and
DNMTs protein in A549/DPP and SPC-A1/DPP as well
as their parental cell lines using Q-RT-PCR and Western
blot, respectively. The results showed that miR-148b had-A1/DDP cells. (A) After A549/DDP and SPC-A1/DDP cells transfected
oses of cisplatin (10, 20, 40, 80, 160, 320 μmol/L) for 48 h , and then
imic is 55.36 μmol/L, IC50NC is 173.27 μmol/L; in SPC-A1/DDP cell,
49 and SPC-A1 cells transfected by miR-148b inhibitor or NC for 24 h,
) for 48 h, and then cells viability was assessed by MTT assay. In A549 cell,
IC50miR-148b inhibitor is 44.62 μmol/L, IC50NC is 6.97 μmol/L. (C) After
th 10 μmol/L cisplatin for 48 h, cells apoptosis was evaluated using flow
lls treated with the same concentration of ciaplatin accordingly.
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cells and an average of 2.5-fold lower expression level in
SPC-A1/DPP cells than that in A549 cells and SPC-A1
cell, respectively (P < 0.05, Figure 2A). On the contrary,
the expression of DNMT1, DNMT3a and DNMT3b was
upregulated in A549/DPP and SPC-A1/DPP cell lines
(Figure 2B).
Upregulation of miR-148b increased sensitivity of the
A549/DDP and SPC-A1/DPP cells to cisplatin
To investigate whether miR-148b could modulate the
sensitivity of the A549/DPP and SPC-A1/DPP as well
as their parental cell lines to cisplatin, we transfected
cisplatin-resistant cells with mimics of miR-148b and
their parental cells with inhibitors of miR-148b, respect-
ively, and then the cells were treated with a series of con-
centrations of cisplatin. We got the data that the mimics
of miR-148b increased the sensitivity to cisplatin signifi-
cantly by 1.5-fold in A549/DDP and SPC-A1/DPP cells
(P < 0.05, respectively; Figure 3A), however, sensitivities
of A549 and SPC-A1 cells transfected with miR-148b
inhibitor to cisplatin were decreased compared with that
treated with NC (P < 0.05, respectively; Figure 3B). To fur-
ther assess the role of miR-148b in regulating growth of
A549/DDP and SPC-A1/DPP cells exposed to cisplatin,
cells apoptosis rate that had been transfected with miR-
148b mimic were analyzed using flow cytometry assay. As
shown in Figure 3C, compared with NC, miR-148b mimic
promoted cisplatin-induced apoptosis of A549/DDP and
SPC-A1/DPP cells (P < 0.05, respectively).
MiR-148b regulates expression of DNMT1
To determine whether miR-148b is involved in regulation
the expression of DNMTs, A549/DDP and A549 cells
were transfected with the mimics or inhibitors of miR-Figure 3 miR-148a modified expression of DNMTs. A549/DDP and A-549 c
ainhibitor for 24 h. Expressions of DNMT1, DNMT3a and DNMT3b in cells w
(B) A549 cells.148b respectively, and the expression levels of DNMTs
were determined by Western blot. Figure 4A showed that
transfected mimics of miR-148b resulted in downregu-
lating expression of DNMT1 in A549/DDP cells, but
mimics of miR-148b exerted no effect on expression of
DNMT3a and DNMT3b. In addition, expression of
DNMT1 in A549 transfected with miR-148b inhibitor
was upregulated, however, expressions of DNMT3a and
DNMT3b were not changed (Figure 4B).
Targeting site of miR-148 in the DNMT1 3′UTR
DNMT1 was regarded as a potential target gene of miR-
148b using TargetScan Release 5.2 in which we found a
binding site for miR-148b in the 3′UTR of DNMT1 mRNA
(Figure 1A). To confirm DNMT1 as a real miR-148b target,
the entire 3′UTR of DNMT1 was inserted downstream of
the luciferase gene and assayed in A549/DDP and A549
cells. As shown in Figure 1B, cotransfection of miR-148b
mimics with the DNMT1 3′UTR reporter resulted in a de-
crease (40%) in luciferase activity and a highly significant
decline in mRNA of DNMT1 in A549/DDP cells. Addition-
ally, Figure 1C showed increases (2.3 fold) in luciferase
activity and mRNA of DNMT1 in A549 transfected with
miR-148b inhibitor and the DNMT1 3′UTR reporter.
These data suggested a might involvement of DNMT1
in modulating the cisplatin sensitivity by miR-148b in
the A549/DPP and A549 cells.
DNMT1 siRNA increases cisplatin sensitivity of A549/DDP
and SPC-A1/DPP cells
To demonstrate the effect of DNMT1 on cisplatin sensi-
tivity of lung cancer cells, the DNMT1 siRNA or siRNA
negative control was transfected into the A549/DDP and
SPC-A1/DPP cells to observe cell viability. We first mea-
sured the expression of DNMT1 using western blot andells were separately transfected by NC or miR-148b mimic or miR-148b
ere determined using western blot assay in (A) A549/DDP cells and
Figure 4 Targeting site of miR-148b in the DNMT1 3′UTR. (A) DNMT1 3′UTR was predicted a binding site for hsa-miR-148b. The mouse DNMT1
mRNA sequence is shown with potential binding sites indicated in white. The highly conserved mature miR-148b sequence in mammals
and potential binding between the miR-148b seed region to the mouse DNMT1 3′UTR sequence are shown. (B) After A549/DDP transfected
with miR-148b mimic for 24 h, binding of miR-148b and DNMT1 was assessed by Luciferase reporter assays and expression of DNMT1 mRNA
was assessed using Q-RT-PCR. (C) After A549 transfected with miR-148b ainhibitor for 24 h, binding of miR-148b and DNMT1 was assessed
by Luciferase reporter assays and expression of DNMT1 mRNA was assessed using Q-RT-PCR. Data were represented as mean ± SD. *P <0.05
compared with NC
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DDP cell (Figure 5A) and SPC-A1/DPP cell (Figure 5C).
To further investigate the effect of DNMT1 on cisplatin-
resistant cell chemoresistance, we analyzed the sensitivity
of A549/DDP and SPC-A1/DPP cells to a series concen-
trations of ciaplatin after knock-down of DNMT1. The
growth-inhibitory activities of ciaplatin in the A549/DDP-
DNMT1 and SPC-A1/DPP-DNMT1 were 1.2-fold lower
than that in control cells (P < 0.05, repectively; Figure 5B
and D). These demonstrate that down-regulation of
DNMT1 could reverse the resistance of A549/DDP cells
as well as SPC-A1/DPP to ciaplatin.Overexpression of DNMT1 reverses miR-148b-increased
cisplatin sensitivity of A549/DDP cells
To conform the regulating role of DNMT1 in miR-148b
modulating the cisplatin sensitivity of the A549/DPP cells,
the pcDNA3.1-DNMT1 or pcDNA3.1 negative control
was transfected into the A549/DDP cells. Western blot
assay showed an increased expression of DNMT1 in
A549/DDP cells cotransfected with pcDNA3.1-DNMT1
and miR-148b mimics (P < 0.05, Figure 6A). Next, cells
were treated with a series concentration of ciaplatin to
evaluate cells viability by MTTassay. As shown in Figure 6B,
compared with miR-148b mimic NC, A549/DDP cells
Figure 5 Effect of downregulated DNMT1 on cisplatin sensitivity of A549/DDP and SPC-A1/DDP cells. (A) A549/DDP cells were transfected with
si-DNMT1. (B) 24 hours after incubation, the cell viability was assessed by MTT assay. (C) SPC-A1/DDP cells were also transfected with si-DNMT1
and (D) its cell viability was evaluated. Data were represented as mean ± SD. *P <0.05 compared with cells treated with the same concentration
of ciaplatin accordingly.
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increased cisplatin sensitivity of A549/DDP cells (P < 0.05).
Consistent with this data, apoptosis in A549/DDP cells
transfected with pcDNA3.1-DNMT1 was lower than that
in cells transfected with miR-148b mimic NC (P < 0.05,
Figure 6C).Discussion
Cisplatin-based chemotherapy is the first-line chemo-
therapy for advanced-stage patients in various cancers at
present. Despite a high rate of initial response, 5-year
patient survival rate is very low resulting from tumors
developing resistance to therapy [13]. Thus, an intense
research underlying chemoresistance should be conducted
to further establish better therapeutic approaches. In this
research, we first detected the impact of miR-148b ex-
pression on ciaplatin resistance in NSCLC cells line and
the results showed that miR-148b was notably down-
regulated in cisplatin-resistant NSCLC cell line (A549/
DDP). The further analysis indicated that DNMT1 is theimportant target for miR-148b in the development of
cisplatin resistance in NSCLC cells .
miR-148b is a member of miR-148/152 family, which
has the mature structure of 21–22 nucleotides in length
and the same seed sequence of approximately 6–7 nucleo-
tides [14]. It has been demonstrated that down-regulated
miR-148b is correlated with tumor formation, distant me-
tastasis or worse prognosis in colorectal and gastric cancer
[7,8] and it also suppressed proliferation and migration of
NSCLC cells [11] However, the study in relationship be-
tween miR-148b and chemotherapy resistance is very rare.
Interestingly, as a member of miR-148/152 family, miR-
148a plays an important role in improving response to
chemotherapy in sensitive and resistant cancers, such as
oesophageal adenocarcinoma and squamous cell carcin-
oma cells [15] and hormone-refractory prostate cancer
[16]. In this study, we focus on the changes in miR-
148b expression and hypothesized its involvement in
chemotherapy resistance of NSCLC. Our data showed
the down-regulated expression of miR-148b in A549/
DDP and SPC-A1/DPP cells compared with their parental
Figure 6 Effect of overexpressed DNMT1 on cisplatin sensitivity of A549/DDP cells. A549/DDP cells transfected with pcDNA3.1-DNMT1 or pcDNA3.1
were used in experiments. (A) Expression of DNMT1 was evaluated using western blot assay. (B) After transfected with miR-148b mimic for 24 h, cells
were incubated with various doses of cisplatin (10, 20, 40, 80, 160, 320 μmol/L), and then cell viability was assessed using MTT assay. (C) After transfected
with miR-148b mimic24 for 24 h, cells were incubated with 10 μmil/L cisplatin, and then cell apoptosis was determined using flow cytometry. Data were
represented as mean ± SD. *P <0.05 compared with NC; #P <0.05 compared with miR-148b mimic.
Sui et al. Journal of Translational Medicine  (2015) 13:132 Page 8 of 9cell lines. Importantly, over-expression of miR-148b in-
creased the sensitivity of A549/DDP as well as SPC-A1/
DPP cells to cisplatin measured by MTTand flow cytome-
try assay. Therefore, the results indicated that miR-148b
could play a crucial role in the development of cisplatin
resistance in NSCLC.DNMTs is a kind of most abundant DNA methyltrans-
ferase in mammalian cells and mediate the transfer of
methyl groups from S-adenosylmethionine to the 5 pos-
ition of cytosine bases in the dinucleotide sequence CpG
[17]. DNMTs play an important role in the epigenetic pro-
cesses that including gene expression and the maintenance
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onstrated that DNMTs mediated transcriptional silencing
in malignant tumors as well as in lung cancer. In this study,
we also detected up-regulated DNMT1, DNMT3a and
DNMT3b in A549/DDP cells. DNMTs regulation by miR-
148/152 family members has been reported in a number
of human diseases [18,19]. However, the result in our
research indicated that only DNMT1 was regulated by
miR-148a. In addition, Xiang et al. reported that DNMT1
is a key target for miR-152 and miR-185 in ovarian cancer
cisplatin resistance in vitro and in vivo [20]. DNMT1 was
also involved in gastric carcinomas treated by neoadjuvant
chemotherapy [21]. These results suggest that DNMT1 is
an key target gene for miRNAs in development of chemo-
therapy resistance. Consistent with this, the result of
TargetScan Release in our research indicated that DNMT1
acted as a potential target gene for miR-148b in its mRNA
3′UTR. Further protein expression assay showed that
DNMT1 was up-regulated in A549/DDP, importantly,
its expression was regulated by over-expression or down-
regulation of miR-148b in A549/DDP or A549.
Conclusions
In summary, this study has shown that the development
of drug-resistant NSCLC cells is associated with the de-
regulation of miR-148b expression. Additionally, we have
shown that expression of miR-148b is contradictory rela-
tionship with DNMT1 expression in the A549/DDP cells.
Furthermore, the silence of DNMT1 expression in the
A549/DDP cells reversed miR-148b-induced increases
sensitivity of the drug-resistant cancer cells to cisplatin.
Targeting the expressed miR-148b or its regulated gene
may offer novel therapeutic approaches for the treat-
ment of NSCLC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FM carried out the molecular genetic studies and drafted the manuscript. YL
carried out the MTT assay and cell culture. YJ participated in the design of
the study and performed the statistical analysis. CS conceived of the study,
and participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgement
Chengguang Sui contributed towards the study by making substantial
contributions to conception, design, acquisition of data, or analysis and
interpretation of data. It is also very grateful for all authors make great efforts.
Received: 26 November 2014 Accepted: 14 April 2015
References
1. Chen Y, Peng W, Lu Y, Chen J, Zhu YY, Xi T. MiR-200a enhances the migrations
of A549 and SK-MES-1 cells by regulating the expression of TSPAN1. J Biosci.
2013;38(3):523–32.
2. Calbo J, Meuwissen R, van Montfort E, van Tellingen O, Berns A. Genotype-
phenotype relationships in a mouse model for human small-cell lung cancer.
Cold Spring Harb Symp Quant Biol. 2005;70:225–32.3. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al.
Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4
data. Lancet Oncol. 2007;8(9):784–96.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell.
2004;116(2):281–97.
5. Chitwood DH, Timmermans MC. Small RNAs are on the move. Nature.
2010;467(7314):415–9.
6. Zhao G, Zhang J-G, Liu Y, Qin Q, Wang B, Tian K, et al. MiR-148b functions
as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Mol Cancer
Ther. 2013;12(1):83–93.
7. Azizi M, Teimoori-Toolabi L, Arzanani MK, Azadmanesh K, Fard-Esfahani P,
Zeinali S. MicroRNA-148b and microRNA-152 reactivate tumor suppressor
genes through suppression of DNA methyltransferase-1 gene in pancreatic
cancer cell lines. Cancer Biol Ther. 2014;15(4):0–1.
8. Wang G, Cao X, Lai S, Luo X, Feng Y, Wu J, et al. Altered p53 regulation of
miR-148b and p55PIK contributes to tumor progression in colorectal cancer.
Oncogene. 2014;34(7):912–21.
9. Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, et al. MicroRNA-148b is
frequently down-regulated in gastric cancer and acts as a tumor suppressor
by inhibiting cell proliferation. Mol Cancer. 2011;10(1):1.
10. Sandhu R, Rivenbark AG, Mackler RM, Livasy CA, Coleman WB. Dysregulation
of microRNA expression drives aberrant DNA hypermethylation in basal-like
breast cancer. Int J Oncol. 2014;44(2):563–72.
11. Liu GL, Liu X, Lv XB, Wang XP, Fang XS, Sang Y. miR-148b functions as a
tumor suppressor in non-small cell lung cancer by targeting carcinoembryo-
nic antigen (CEA). Int J Clin Exp Med. 2014;7((8):1990.
12. Tang M1, Xu W, Wang Q, Xiao W, Xu R. Potential of DNMT and its epigenetic
regulation for lung cancer therapy. Curr Genomics. 2009;10(5):336–52.
13. Wozniak AJ, Gadgeel SM. Adjuvant therapy for resected non-small cell lung
cancer. Ther Adv Med Oncol. 2009;1(2):109–18.
14. Chen Y, Song YX, Wang ZN. The microRNA-148/152 family: multi-faceted
players. Mol Cancer. 2013;12:3.
15. Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, et al. Mir-148a
improves response to chemotherapy in sensitive and resistant oesophageal
adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg.
2011;15(3):429–38.
16. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, et al. MiR-148a
attenuates paclitaxel resistance of hormone-refractory, drug-resistant
prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem.
2010;285(25):19076–84.
17. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter
hypermethylation. N Engl J Med. 2003;349(21):2042–54.
18. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA,
et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate
mRNA expression in normal tissues and overexpression in tumors. Nucleic
Acids Res. 1999;27(11):2291–8.
19. Tennis MA, VanScoyk MM, Wilson LA, Kelley N, Winn RA. Methylation of Wnt7a
is modulated by DNMT1 and cigarette smoke condensate in non-small
cell lung cancer. PLoS One. 2012;7(3), e32921.
20. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, et al. MiR-152 and miR-185
co-contribute to ovarian cancer cells cisplatin sensitivity by targeting
DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Oncogene. 2013;33(3):378–86.
21. Mutze K, Langer R, Schumacher F, Becker K, Ott K, Novotny A, et al. DNA
methyltransferase 1 as a predictive biomarker and potential therapeutic
target for chemotherapy in gastric cancer. Eur J Cancer. 2011;47(12):1817–25.
